• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

PIK-75

Product ID P333400
Cas No. 372196-67-3
Purity ≥99%
Product Unit SizeCostQuantityStock
5 mg $74.10 In stock
25 mg $179.30 In stock
100 mg $525.40 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PIK-75 is a selective inhibitor of p110α, an isoform of PI3K. When combined with gemcitabine, PIK-75 reduced NRF2 protein levels, augmenting the antitumor effect of gemcitabine in human pancreatic cancer cell lines. PIK-75 was chosen over several other PI3K/Akt pathway inhibitors and used with the Braf inhibitor vemurafenib in models of advanced melanoma.

Product Info

Cas No.

372196-67-3

Purity

≥99%

Formula

C16H14BrN5O4S

Formula Wt.

452.28

Chemical Name

PIK-75

IUPAC Name

N'-[(E)-(6-Bromoimidazo[1,2-a]pyridin-3-yl)methylene]-N,2-dimethyl-5-nitrobenzenesulfonohydrazide

Synonym

PIK 75, PIK75

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

P333400 MSDS PDF

Info Sheet

P333400 Info Sheet PDF

References

Duong H., Yi Y., et al. Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine. Int J Oncol. 44(3):959-69 (2014). PMID: 2436609.

Pedini F., De Luca G., et al. Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma. Mol Oncol. 2019. PMID: 31115969.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only